Rayno Diagnostics and Tools Market Update: GenProbe (GPRO),Illumina (ILMN),Quidel (QDEL)
Earnings season has begun with good results. Keep in mind the following trends: technology convergence, molecular diagnostics and M&A. The backdrop for the tools market is proposed government cuts in government scientific spending especially NIH. Leerink Swann data from the Dept. of Health...
Rayno Life Science Portfolio Dx and Tools: GenProbe (GPRO) Soars On “For Sale”
Earnings season for diagnostics and tools companies begins today with GenProbe (GPRO $79.39) after the market close. But the stock is up 13% today on a Bloomberg scoop that the Company has hired Morgan Stanley as an investment banker to seek a buyer. The market cap is $3.8B with a 2011...
Biotech Rocks On: Rayno Life Science Portfolio Up 2.2 % Led By Regeneron (REGN)
The biotech bulls are in charge this week. The sellers must have been watching the Bernanke Press Conference today or maybe buying gold as biotech stocks had one of their best days of the year. The bellwether ETF IBB was up 2.37% to $108.71 an all time high exceeding its high of $105 in June of...
Biotech Sector Ignited By Biogen-Idec (BIIB) and Vertex (VRTX)
Vertex (VRTX $54.17) soared 12.75% today on expectations for FDA approval of it telaprevir HCV drug Thursday April 28. Today FDA staff in a preliminary review commented that the Vertex drug when combined with current therapies is more effective than those drugs alone. The FDA team confirmed...
Rayno Life Science Market ReCap-Quiet Day but More Red than Green
Caution is still on as we have had big moves YTD and speculative stocks are selling off. High flyers Amarin (AMRN $16.10) is down 4.85% on volume of 6.85M shares while Ariad (ARIA $8.14) was down 3.2% on volume of 1.5M shares.. Vertex(VRTX $48.04) down 2.69% coinciding with comments from the...